PT  - JOURNAL ARTICLE
AU  - YUKO OYA
AU  - TATSUYA YOSHIDA
AU  - HIROAKI KURODA
AU  - JUNICHI SHIMIZU
AU  - YOSHITSUGU HORIO
AU  - YUKINORI SAKAO
AU  - TOYOAKI HIDA
AU  - YASUSHI YATABE
TI  - Clinical Efficacy of Alectinib in Patients with <em>ALK</em>-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure
DP  - 2017 Nov 01
TA  - Anticancer Research
PG  - 6477--6480
VI  - 37
IP  - 11
4099  - http://ar.iiarjournals.org/content/37/11/6477.short
4100  - http://ar.iiarjournals.org/content/37/11/6477.full
SO  - Anticancer Res2017 Nov 01; 37
AB  - Several second-generation inhibitors of anaplastic lymphoma kinase (ALK) have demonstrated potent activity in ALK rearrangement-positive non-small cell lung cancer (NSCLC). Two of these agents, ceritinib, and alectinib, recently received approval for the treatment of ALK-rearranged NSCLC in Japan. The efficacy of treatment with a second-generation ALK inhibitor after failure with a different second-generation ALK inhibitor remains unclear. We present a series of eight patients with ALK-rearranged NSCLC treated with alectinib who experienced disease progression after ceritinib. Both crizotinib and ceritinib were administered to six patients, with four (29%) patients receiving crizotinib followed by ceritinib. Among the eight study patients, two (25%) had partial response, one (12%) stable disease, and five (63%) had progressive disease. The median progression-free survival was 3.6 months (95% confidence interval=0-7.1 months). The results of this study suggest that the second-generation ALK inhibitor alectinib has limited efficacy after initial treatment with the second-generation ALK inhibitor ceritinib.